ACA
AKBA icon

Avoro Capital Advisors’s Akebia Therapeutics AKBA Stock Holding History

Avoro Capital Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-456,369
Closed -$4.2M – 47
2017
Q1 		$4.2M Sell
456,369
-375,146
-45% -$3.66M 0.54% 32
2016
Q4 		$8.66M Sell
831,515
-113,064
-12% -$974K 1.75% 20
2016
Q3 		$8.55M Buy
944,579
+322,706
+52% +$2.74M 1.5% 21
2016
Q2 		$4.65M Buy
+621,873
New +$5.43M 1.03% 24

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avoro Capital Advisors's AKBA Position: Q2 2017 in Review

Avoro Capital Advisors sold out of Akebia Therapeutics (AKBA) in Q2 2017, closing a stake of 456,369 shares — an estimated $4.2M sold.

Avoro Capital Advisors first reported a position in AKBA in Q2 2016 and held it in 4 quarters. The position peaked at $8.66M in Q4 2016. 118 funds tracked by Wall St. Rank hold AKBA as of Q2 2017.

  • Avoro Capital Advisors reported no remaining Akebia Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Avoro Capital Advisors sold 456,369 Akebia Therapeutics shares in Q2 2017, an estimated $4.2M.
  • Avoro Capital Advisors first reported a position in Akebia Therapeutics in Q2 2016 and held it in 4 quarters.
  • Avoro Capital Advisors's Akebia Therapeutics position peaked at $8.66M in Q4 2016.
  • 118 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2017.

Based on Avoro Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.